Characteristic  No.  Hazard ratio (95% CI)   p value for intervention (ANOVA) p value for interaction
Sex, no. of patients         0.80
Male       0.96  
Nano 49 0.92 (0.73 to 1.06)    
Ferro 44 0.89 (0.69 to 1.09)    
Stent 46 0.92 (0.76 to 1.07)    
Female       0.79  
Nano 11 0.78 (0.49 to 0.99)    
Ferro 16 0.85 (0.56 to 1.05)    
Stent 14 0.89 (0.63 to 1.06)    
Smoking, no.         0.27
Never       0.09  
Nano 9 0.75 (0.64 to 0.94)    
Ferro 11 0.57 (0.43 to 0.98)    
Stent 7 0.62 (0.59 to 0.88)    
Stopped/ Current       0.89  
Nano 51 0.89 (0.76 to 1.19)    
Ferro 49 0.81 (0.68 to 1.14)    
Stent 53 0.87 (0.72 to 1.19)    
Alcohol abuse, no.         0.97
Yes       0.94  
Nano 29 0.57 (0.36 to 1.01)    
Ferro 37 0.69 (0.45 to 0.87)    
Stent 25 0.64 (0.33 to 0.94)    
No       0.98  
Nano 31 0.93 (0.59 to 1.12)    
Ferro 23 0.87 (0.85 to 1.11)    
Stent 35 0.85 (0.69 to 1.06)    
Baseline PAV, %         0.79
< Mean       0.97  
Nano 22 0.89 (0.66 to 1.01)    
Ferro 21 0.85 (0.58 to 0.98)    
Stent 26 0.86 (0.55 to 0.93)    
≥ Mean       0.78  
Nano 38 0.43 (0.16 to 0.49)    
Ferro 39 0.32 (0.01 to 0.62)    
Stent 34 0.38 (0.09 to 0.72)    
Baseline MLD, mm         0.84
< Mean       0.72  
Nano 36 0.32 (0.16 to 0.73)    
Ferro 33 0.39 (0.04 to 0.58)    
Stent 31 0.49 (0.34 to 0.69)    
≥ Mean       0.92  
Nano 24 0.69 (0.49 to 0.87)    
Ferro 27 0.75 (0.58 to 0.77)    
Stent 29 0.77 (0.54 to 0.94)    
Baseline calcium, mm2*         0.97
< Mean       0.99  
Nano 28 0.74 (0.54 to 0.85)    
Ferro 23 0.69 (0.58 to 0.88)    
Stent 25 0.76 (0.54 to 0.86)    
≥ Mean       0.96  
Nano 32 0.49 (0.37 to 0.61)    
Ferro 37 0.53 (0.39 to 0.66)    
Stent 35 0.64 (0.54 to 0.68)    
Baseline necrotic core, mm2*         0.047
< Mean       0.031  
Nano 36 0.46 (0.39 to 0.49)    
Ferro 39 0.58 (0.52 to 0.71)    
Stent 33 0.74 (0.64 to 0.85)    
≥ Mean       0.048  
Nano 24 0.73 (0.56 to 0.98)    
Ferro 21 0.87 (0.76 to 0.97)    
Stent 27 0.39 (0.34 to 0.72)    
Baseline fibrous, mm2*         0.63
< Mean       0.41  
Nano 28 0.56 (0.36 to 0.86)    
Ferro 23 0.37 (0.14 to 0.53)    
Stent 24 0.54 (0.34 to 0.78)    
≥ Mean       0.69  
Nano 32 0.55 (0.35 to 0.80)    
Ferro 37 0.48 (0.28 to 0.70)    
Stent 36 0.56 (0.37 to 0.63)    
Baseline fibro-fatty, mm2*         0.068
< Mean       0.83  
Nano 29 0.75 (0.55 to 1.01)    
Ferro 26 0.78 (0.50 to 0.99)    
Stent 24 0.79 (0.53 to 0.93)    
≥ Mean       0.049  
Nano 31 0.75 (0.61 to 1.06)    
Ferro 34 0.54 (0.35 to 0.68)    
Stent 36 0.69 (0.55 to 1.01)    
                                 
PAV regression below 40% Glagov threshold PAV regression above 40% Glagov threshold
Table 4: Prespecified subgroup analysis of change in plaque burden from baseline to follow-up at 12 months (intention-to-treat analysis).